Taysha Gene Therapies Statistics Share Statistics Taysha Gene Therapies has 272.68M
shares outstanding. The number of shares has increased by 33.05%
in one year.
Shares Outstanding 272.68M Shares Change (YoY) 33.05% Shares Change (QoQ) 4.26% Owned by Institutions (%) 76.17% Shares Floating 222.28M Failed to Deliver (FTD) Shares 22,497 FTD / Avg. Volume 0.42%
Short Selling Information The latest short interest is 43.36M, so 15.89% of the outstanding
shares have been sold short.
Short Interest 43.36M Short % of Shares Out 15.89% Short % of Float 17.76% Short Ratio (days to cover) 10.08
Valuation Ratios The PE ratio is -4.85 and the forward
PE ratio is -11.9.
Taysha Gene Therapies's PEG ratio is
0.08.
PE Ratio -4.85 Forward PE -11.9 PS Ratio 51.93 Forward PS 233.2 PB Ratio 6.05 P/FCF Ratio -5.3 PEG Ratio 0.08
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Taysha Gene Therapies.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.42,
with a Debt / Equity ratio of 0.88.
Current Ratio 5.42 Quick Ratio 5.42 Debt / Equity 0.88 Debt / EBITDA -0.72 Debt / FCF -0.77 Interest Coverage -896.66
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $114.15K Profits Per Employee $-1.22M Employee Count 73 Asset Turnover 0.05 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 136.82% in the
last 52 weeks. The beta is 0.97, so Taysha Gene Therapies's
price volatility has been higher than the market average.
Beta 0.97 52-Week Price Change 136.82% 50-Day Moving Average 3.02 200-Day Moving Average 2.25 Relative Strength Index (RSI) 77.21 Average Volume (20 Days) 5,339,469
Income Statement In the last 12 months, Taysha Gene Therapies had revenue of 8.33M
and earned -89.3M
in profits. Earnings per share was -0.36.
Revenue 8.33M Gross Profit 8.33M Operating Income -91.46M Net Income -89.3M EBITDA -87.95M EBIT -89.2M Earnings Per Share (EPS) -0.36
Full Income Statement Balance Sheet The company has 139.04M in cash and 63.18M in
debt, giving a net cash position of 75.86M.
Cash & Cash Equivalents 139.04M Total Debt 63.18M Net Cash 75.86M Retained Earnings -602.3M Total Assets 333.33M Working Capital 290.92M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -81.22M
and capital expenditures -374K, giving a free cash flow of -81.6M.
Operating Cash Flow -81.22M Capital Expenditures -374K Free Cash Flow -81.6M FCF Per Share -0.33
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -1097.55% and -1071.62%.
Gross Margin 100% Operating Margin -1097.55% Pretax Margin -1071.62% Profit Margin -1071.62% EBITDA Margin -1055.45% EBIT Margin -1097.55% FCF Margin -979.23%
